Loading...
Docoh

Ovid Therapeutics (OVID)

Utility
Use of Gaboxadol, Ganaxolone and Allopregnanolone to Treat Movement Disorders
14 Apr 22
Use of gaboxadol, allopregnanolone, or ganaxolone, or a pharmaceutical salt of any of the foregoing, for the treatment of cervical dystonia, multiple system atrophy, myoclonus, progressive supranuclear palsy, restless legs syndrome, Wilson's disease, ataxia, chorea, or dystonia in a subject in need thereof.
Matthew DURING
Filed: 21 Dec 21
Utility
Use of gaboxadol in the treatment of diabetes and related conditions
5 Apr 22
Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease.
Matthew During
Filed: 8 Oct 20
Utility
Methods for treating aggression associated with Alzheimer's disease
22 Mar 22
Methods of treating aggression associated with Alzheimer's Disease including administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient.
Matthew During
Filed: 29 Jun 18
Utility
Pharmaceutical Formulations Containing Gaboxadol for Therapeutic Treatment
10 Feb 22
Pharmaceutical formulations containing gaboxadol or a pharmaceutically acceptable salt thereof and methods of treating essential tremors, Tourette syndrome or Fragile X syndrome are provided.
Matthew DURING
Filed: 21 Oct 21
Utility
Methods of Increasing Tonic Inhibition and Treating Secondary Insomnia
20 Jan 22
Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed.
Matthew During
Filed: 30 Sep 21
Utility
Treatment of Depressive Disorders
9 Dec 21
Formulations for treating depressive disorders and methods for treating depressive disorders using gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Matthew DURING
Filed: 18 Aug 21
Utility
Recombinant Adeno-associated Vectors
2 Dec 21
Adeno-associated virus (AAV) vectors and uses thereof are provided.
Matthew DURING
Filed: 12 Aug 21
Utility
Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
28 Sep 21
Expression of micoRNAs that negatively regulate the activity of the SNHG14 gene for can be used in treatment of Angelman Syndrome.
Matthew During
Filed: 7 Jul 20
Utility
Methods of Treating Attention Deficit Hyperactivity Disorder
16 Sep 21
Methods and compositions for treating Attention-deficit/hyperactivity disorder are provided which include administering to a patient in need thereof captodiamine or a pharmaceutically acceptable salt thereof.
Matthew During
Filed: 2 Jun 21
Utility
Methods of treating developmental disorders with gaboxadol
24 Aug 21
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Matthew During
Filed: 17 Dec 18
Utility
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
17 Aug 21
Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew During
Filed: 20 Aug 20
Utility
Methods and Compositions for Treatment of Epileptic Disorders
15 Jul 21
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew DURING
Filed: 30 Mar 21
Utility
GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
24 Jun 21
Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.
Matthew DURING
Filed: 18 Dec 20
Utility
Use of Gaboxadol In the Treatment of Gastrointestinal Tract Disorders and Asthma
17 Jun 21
Treatment of irritable bowel syndrome, Crohn's disease, celiac disease, ulcerative colitis, microscopic colitis, and asthma using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew DURING
Filed: 22 Aug 19
Utility
Use of (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC Acid and Related Compounds, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC Acid and Vigabatrin In the Treatment of Developmental Disorders
8 Apr 21
Methods and compositions for use treating Fragile X syndrome, Angelman syndrome, Fragile X-associated tremor/ataxia syndrome, Autism Spectrum Disorder, Asperger's syndrome, Pervasive developmental disorder not otherwise characterized, Childhood Disintegrative Disorder, Williams syndrome, or Jacobsen syndrome with a compound of Formula 1 as described herein, (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid, or vagabatrin, or pharmaceutically acceptable salts of any of the foregoing, are provided.
Matthew DURING, Brett ABRAHAMS
Filed: 16 Oct 20
Utility
Use of MIR101 or MIR128 In the Treatment of Seizure Disorders
1 Apr 21
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient.
Matthew DURING
Filed: 17 Nov 20
Utility
Methods of treating developmental disorders and/or seizure disorders with etifoxine
23 Feb 21
Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided.
Matthew During
Filed: 13 Aug 19
Utility
Methods of Treating Developmental Disorders with Gaboxadol
4 Feb 21
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X—associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Matthew DURING
Filed: 25 Jun 20
Utility
Use of Gaboxadol In the Treatment of Diabetes and Related Conditions
4 Feb 21
Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease.
Matthew During
Filed: 8 Oct 20
Utility
Pharmaceutical Formulations Containing Gaboxadol for Therapeutic Treatment
21 Jan 21
Pharmaceutical formulations containing gaboxadol or a pharmaceutically acceptable salt thereof and methods of treating essential tremors, Tourette syndrome or Fragile X syndrome are provided.
Matthew DURING
Filed: 15 Jul 20
Patents are sorted by USPTO publication date, most recent first